Stout announced that its client, Ada Health has successfully completed its $90 Million Series B financing round led by Leaps by Bayer, the impact investment arm of Bayer AG. Additionally, among others, Vitruvian Partners, F4 and Samsung Catalyst Fund joined the round.

The investment will help advance the company’s popular health assessment technology, enabling the digital health pioneer to accelerate its path toward becoming the world's leading personalized operating system for health, as well as to further grow the company’s leading position in the United States. In addition to today’s announcement, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company’s healthcare businesses.

The Berlin-based Ada Health has developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, to identify and differentiate conditions with a high degree of medical accuracy, and to navigate safely to the right care, at the right time. Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch.

Ada’s core technology is also available in a suite of AI-driven enterprise solutions. The company is collaborating with a range of leading health systems, insurers, life sciences companies, and global non-profit organizations to integrate its symptom assessment and care navigation solutions into a range of digital care journeys to improve outcomes for patients, consumers, and healthcare providers.

The timely detection of diseases is one of the biggest challenges in guiding consumers and patients to appropriate care, with under-diagnosis, misdiagnosis, and long patient journeys to diagnosis and care unfortunately being commonplace. In addition, global healthcare systems are overburdened, with organizations required to meet pressures such as growing and aging populations, emerging comorbidity requiring treatment, and the ongoing pandemic. Ada can help shorten time to diagnosis by providing medical guidance that is relevant, actionable, and effective, and will increasingly leverage personalized data insights to support the prediction and prevention of diseases.

“This funding round will help bring us closer to our goal of improving healthcare outcomes for more than 1 billion people around the world. We’re grateful that Stout helped us to team up with investors who have such an exceptional track record of backing truly transformative technologies and who are committed to helping to scale Ada globally,” said Daniel Nathrath, CEO and co-founder of Ada Health.

“Ada has built the world most powerful and popular AI-based health assessment and care navigation platform. We are excited that Ada has teamed up with these world class investors, such as Leaps by Bayer, Vitruvian Partners, F4, Samsung Catalyst Fund, and others, which also share Ada’s vision of transforming the way people access healthcare. Stout is looking forward to further supporting this journey,” added Mathis Wilke, Managing Director at Stout, who led the execution of the transaction.

Stout Vice President Kevin Kissner assisted on the deal with further support from Stout’s Nansi Nistorova.

See more information on our Investment Banking services.